Size | Price | |
---|---|---|
10mg | ||
25mg | ||
50mg | ||
100mg | ||
250mg |
Purity: ≥98%
A 33853 (A33853; A-33853), a tetraacetyl that contains an anhydride moiety, is an antibiotic originally isolated from culture broth of Streptomyces sp. The synthetic analog of it was screened for the inhibition of L. donovani, T. b. rhodesiense, T. cruzi, and P. falciparum cultures followed by determination of IC(50) in L. donovani and cytotoxicity on L6 cells revealed one of the analogs compound 31 to be 3-fold more active than miltefosine, a known antileishmanial drug. Other analogs of A 33853 selectively inhibited L. donovani at nanomolar concentrations and showed much lower cytotoxicity.
ln Vitro |
The primary pathogenic bacteria causing coccidiosis, Eimeria tenella, is inhibited by the antibiotic A-33853, and its minimum inhibitory concentration (MIC) against Trichomonas vaginalis is less than 0.975 μg/mL[1].
|
---|---|
ln Vivo |
Chicks are not resistant to Mycoplasma gallisepticum to the extent that antibiotic A-33853 (60 mg/kg; subcutaneous injection; single dose) is [1]. Chicks are not resistant to Mycoplasma gallisepticum to the extent that antibiotic A-33853 (70 mg/kg; subcutaneous injection; single dose) is [1]. 300 mg/kg (intraperitoneal injection) is the LD50 value of the acute toxic dose of antibiotic A-33853 in mouse models [1]. [1] Staphylococcus aureus.
|
References |
[1]. In Pursuit of Natural Product Leads: Synthesis and Biological Evaluation of 2-[3-hydroxy-2-[(3-hydroxypyridine-2-carbonyl)amino]phenyl]benzoxazole-4-carboxylic acid (A-33853) and Its Analogues: Discovery of N-(2-Benzoxazol-2-ylphenyl)benzamides as Novel Antileishmanial Chemotypes J. Med. Chem., 2008, 51 (23), pp 7344-7347
[2]. Michel KH, et al. The discovery, fermentation, isolation, and structure of antibiotic A33853 and its tetraacetyl derivative. J Antibiot (Tokyo). 1984 May;37(5):441-5. |
Molecular Formula |
C20H13N3O6
|
|
---|---|---|
Molecular Weight |
391.34
|
|
CAS # |
80148-45-4
|
|
Related CAS # |
|
|
SMILES |
O=C(C1=C2N=C(C3=CC=CC(O)=C3NC(C4=NC=CC=C4O)=O)OC2=CC=C1)O
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.5553 mL | 12.7766 mL | 25.5532 mL | |
5 mM | 0.5111 mL | 2.5553 mL | 5.1106 mL | |
10 mM | 0.2555 mL | 1.2777 mL | 2.5553 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.